---
figid: PMC9462104__rmdopen-2022-002359f02
pmcid: PMC9462104
image_filename: rmdopen-2022-002359f02.jpg
figure_link: /pmc/articles/PMC9462104/figure/F2/
number: Figure 2
figure_title: ''
caption: 'Efficacy of biological disease modifying antirheumatic drugs targeting the
  IL-6 receptor or ligand and their relative efficacy and/or regulatory approvals
  across immune-mediated inflammatory diseases (based on available data at end of
  December 2020). aNCT02991469 (recruiting); bNCT02776735 (recruiting); cNCT03600805
  (study terminated, results are awaited); d trial terminated early due to sponsor
  decision. For colorblind readers,  is provided in the  (section 7: S7.1). EU, European
  Union; JPN, Japan; RU: Russian Federation; US: United Stated of America.'
article_title: A systematic literature review informing the consensus statement on
  efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition
  with biological DMARDs in immune-mediated inflammatory diseases.
citation: Kastriot Kastrati, et al. RMD Open. 2022;8(2):e002359.
year: '2022'

doi: 10.1136/rmdopen-2022-002359
journal_title: RMD Open
journal_nlm_ta: RMD Open
publisher_name: BMJ Publishing Group

keywords:
- Cytokines
- Autoimmune Diseases
- Inflammation

---
